A sweeping look at more than a decade of New York hospital data has handed Long Island a dubious distinction: the region shoulders an outsized share of the state’s sickle cell disease burden. Hospitals there see a higher proportion of admissions tagged as a major risk of death and rack up the largest total charges for sickle cell stays. Researchers reviewed more than 42,000 hospitalizations from 2009 through 2022 and found that high‑severity and high‑mortality admissions climbed sharply over time. Most patients were young adults and Black, highlighting long‑running racial and regional gaps in care that advocates say have been ignored for far too long.
The analysis came from researchers in the ISEE Lab at NYU’s School of Global Public Health, who tapped New York State’s SPARCS hospital discharge system to assemble an analytic sample of roughly 42,271 inpatient sickle cell disease stays from 2009 to 2022, according to NYU School of Global Public Health. The findings were presented as a conference abstract tied to the American Society of Hematology program, so this is an early look rather than a full peer‑reviewed paper.
Where the burden hits hardest
Long Island stands out in the data. About 10% of sickle cell hospitalizations there were classified as a major risk of death, and the region posted the highest total charges for these stays. New York City still accounted for roughly two‑thirds of the state’s inpatient sickle cell volume, while Central New York and the Hudson Valley turned up with some of the longest average lengths of stay. Across the state, cases tagged as major severity rose to 27%, and hospitalizations at major risk of mortality climbed to about 13% by 2022, up sharply from the start of the study period, as reported in Blood.
Why researchers say severity rose
The study team points to COVID‑19 complications and pandemic‑era disruptions in routine care as likely drivers of the jump in severity. Their recommendations are not subtle: expand access to sickle cell specialists, and make sure front‑line providers are up to speed on current therapy options. Understanding how the disease plays out differently across regions is key to spotting and closing care gaps, said Emmanuel Peprah, director of NYU’s ISEE Lab, according to NYU School of Global Public Health.
Who is affected
Sickle cell disease affects roughly 100,000 people nationwide and is most common among people of African descent, according to the CDC. In the New York hospital data, about 83% of patients were Black, and the largest shares were young adults. Roughly 40% were between 18 and 29 years old and another 32% were 30 to 49, the researchers report in the conference abstract in Blood.
The authors and patient advocates say the findings offer a roadmap for where health systems and local officials could move fastest: more specialty clinics, standardized inpatient pain protocols, and stronger transition support as patients move from pediatric to adult care. Drawn from a conference abstract, the results add weight to recent calls to steer resources toward the regions showing the greatest clinical need, with Long Island now squarely in the spotlight.
